Washington University School of Medicine

Digital Commons@Becker
Open Access Publications
2014

Radiosynthesis and in Vivo Evaluation of Two PET Radioligands
for Imaging α-Synuclein
-Synuclein
Xiang Zhang
Washington University School of Medicine in St. Louis

Hongjun Jin
Washington University School of Medicine in St. Louis

Prashanth K. Padakanti
Washington University School of Medicine in St. Louis

Junfeng Li
Washington University School of Medicine in St. Louis

Hao Yang
Washington University School of Medicine in St. Louis

See next page for additional authors

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Recommended Citation
Zhang, Xiang; Jin, Hongjun; Padakanti, Prashanth K.; Li, Junfeng; Yang, Hao; Fan, Jinda; Mach, Robert H.;
Kotzbauer, Paul; and Tu, Zhade, ,"Radiosynthesis and in Vivo Evaluation of Two PET Radioligands for
Imaging α-Synuclein." Applied Sciences. 4,1. 66-78. (2014).
https://digitalcommons.wustl.edu/open_access_pubs/3711

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been
accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker.
For more information, please contact vanam@wustl.edu.

Authors
Xiang Zhang, Hongjun Jin, Prashanth K. Padakanti, Junfeng Li, Hao Yang, Jinda Fan, Robert H. Mach, Paul
Kotzbauer, and Zhade Tu

This open access publication is available at Digital Commons@Becker: https://digitalcommons.wustl.edu/
open_access_pubs/3711

Appl. Sci. 2014, 4, 66-78; doi:10.3390/app4010066
OPEN ACCESS

applied sciences
ISSN 2076-3417
www.mdpi.com/journal/applsci
Article

Radiosynthesis and in Vivo Evaluation of Two PET
Radioligands for Imaging α-Synuclein
Xiang Zhang 1, Hongjun Jin 1, Prashanth K. Padakanti 1, Junfeng Li 1, Hao Yang 1, Jinda Fan 1,
Robert H. Mach 1, Paul Kotzbauer 2 and Zhude Tu 1,*
1

2

Department of Radiology, Washington University School of Medicine, 510 S. Kingshighway
Boulevard, St. Louis, MO 63110, USA; E-Mails: zhangx@mir.wustl.edu (X.Z.);
hongjunj@mir.wustl.edu (H.J.); ppada@mail.med.upenn.edu (P.K.P.); lij@mir.wustl.edu (J.L.);
yangh@mir.wustl.edu (H.Y.); jindafan@uab.edu (J.F.); rmach@mail.med.upenn.edu (R.H.M.)
Department of Neurology, Washington University School of Medicine, 660 S. Euclid Ave,
St. Louis, MO 63110, USA; E-Mail: kotzbauerp@neuro.wustl.edu

* Author to whom correspondence should be addressed; E-Mail: tuz@mir.wustl.edu;
Tel.: +1-314-362-8487; Fax: +1-314-362-8555.
Received: 30 April 2013; in revised form: 7 February 2014 / Accepted: 27 February 2014 /
Published: 17 March 2014

Abstract: Two α-synuclein ligands, 3-methoxy-7-nitro-10H-phenothiazine (2a,
Ki = 32.1 ± 1.3 nM) and 3-(2-fluoroethoxy)-7-nitro-10H-phenothiazine (2b,
Ki = 49.0 ± 4.9 nM), were radiolabeled as potential PET imaging agents by respectively
introducing 11C and 18F. The syntheses of [11C]2a and [18F]2b were accomplished in a good
yield with high specific activity. Ex vivo biodistribution studies in rats revealed that both
[11C]2a and [18F]2b crossed the blood-brain barrier (BBB) and demonstrated good brain
uptake 5 min post-injection. MicroPET imaging of [11C]2a in a non-human primate (NHP)
confirmed that the tracer was able to cross the BBB with rapid washout kinetics from brain
regions of a healthy macaque. The initial studies suggested that further structural
optimization of [11C]2a and [18F]2b is necessary in order to identify a highly specific
positron emission tomography (PET) radioligand for in vivo imaging of α-synuclein
aggregation in the central nervous system (CNS).
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Abbreviations: α-syn, α-synuclein; BBB, blood-brain barrier; calcd., calculated; CNS, central
nervous system; DBU, 1,8-diazabicyclo[5.4.0]undec-7-ene; DCM, dichloromethane; DMF,
N,N-dimethylformamide; DMSO, dimethyl sulfoxide; EOB, end of bombardment; [18F]FEOTs,
[18F]fluoroethyltosylate; HPLC, high performance liquid chromatography; HRMS, high resolution
mass spectrometry; LBs, Lewy bodies; LNs, Lewy neuritis; NHP, non-human primate; PD,
Parkinson’s disease; PET, positron emission tomography; QC, quality control; RCY, radiochemical
yield; SAR, structure-activity relationship; SD, Sprague Dawley; SUV, standardized uptake value;
TAC, time-activity curve; VMAT2, vesicular monoamine transporter type 2.
1. Introduction
Although Parkinson’s disease (PD) is a degenerative neurological disorder characterized by motor
symptoms, it is also known to be closely associated with dementia [1]. The primary neuropathologic
change in PD, the degeneration of dopaminergic neurons, occurs in the substantia nigra, accompanied
by Lewy bodies (LB) and Lewy neurites (LN). To date, the pathogenic mechanism of PD is not fully
understood [2]. The diagnosis of PD is primarily based on the clinical symptoms, such as resting
tremor, bradykinesia and rigidity. Because the current treatment for PD is to minimize the disease
symptoms in the patients [1,3], a method of diagnosing PD at a very early stage would greatly help
physicians to design the therapy accordingly.
α-Synuclein (α-syn) is a presynaptic terminal protein that consists of 140 amino acids; the
aggregation of α-syn is considered the pathological hallmark of PD. α-Syn plays an important role in
the central nervous system (CNS) in synaptic vesicle recycling; it also regulates the synthesis, storage
and release of neurotransmitters [4]. It is specifically upregulated in a discrete population of
presynaptic terminals of the brain during acquisition-related synaptic rearrangement [5]. α-Syn
naturally exists in a highly soluble, unfolded state [6,7]. However, in PD brains, insoluble aggregation
of misfolded fibrillar α-syn occurs in LB and LN, which may cause synaptic dysfunction and neuronal
cell death [8–11]. Positron emission tomography (PET) is a non-invasive imaging modality that can
provide the functional information of a living subject at the molecular and cellular level. Current
diagnostic PET radioligands for PD target either the dopaminergic system (pre-synaptic and
post-synaptic dopamine activity) or vesicular monoamine transporter type 2 (VMAT2) [12,13].
Unfortunately, such imaging strategies have difficulty in distinguishing PD from other parkinsonian
syndromes that also result in the degeneration of nigrostriatal projections [14,15]. In addition,
dopaminergic medications used for symptomatic treatment may alter striatal uptake of these agents,
limiting their reliability for measuring disease progression [16]. In contrast, α-syn is a valuable
imaging target for PD, because fibrillar α-syn deposition in LB and LN distinguishes PD from other
disorders and is the defining feature for post-mortem pathologic diagnosis. Thus, a small molecular
PET radiotracer with high affinity and selectivity to fibrillar α-syn protein could be used to quantify
the level of α-syn aggregation non-invasively. This will not only improve the diagnostic accuracy of
PD, but also provide a tool to improve the understanding of disease progression and monitor the
therapeutic efficacy in clinical trials.
Our group previously reported the syntheses of a class of tricyclic analogues and their in vitro
binding affinities towards α-syn fibrils; several lead compounds were identified with moderate
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affinities for α-syn fibrils (Ki < 70 nM) (Figure 1, 2a, 2b) [17]. Compounds 2a and 2b also displayed
favorable binding selectivity to α-synuclein aggregation compared to Aβ and tau protein: for 2a,
Ki-α-syn/Ki-Aβ > 3-fold and Ki-α-syn/Ki-tau > 4-fold; for 2b, Ki-α-syn/Ki-Aβ = 2.1-fold and
Ki-α-syn/Ki-tau = 2.5-fold [18]. The radioiodinated ligand, [125I]1, was synthesized to establish a
methodology for screening the α-syn fibril binding affinity of new ligands using a competition binding
assay [18]. The affinities for 2a and 2b were determined using this [125I]1 assay, and the resulting Ki
values (66.2 nM for 2a, 19.9 nM for 2b) were in the same range as the values obtained by the
Thioflavin T assay. The 125I competition assay further confirmed the previously determined in vitro
potency of 2a and 2b, which were developed as potential PET radioligands to be radiolabeled by 11C
or 18F. In the current manuscript, we report the radiosyntheses of [11C]2a and [18F]2b and their
validation in animal studies to determine whether [11C]2a and [18F]2b can penetrate the blood-brain
barrier (BBB), have sufficient brain uptake and fast washout from the brain. Results of ex vivo
biodistribution of [11C]2a and [18F]2b in Sprague-Dawley rats and microPET CNS imaging in a
cynomolgus macaque of [11C]2a suggest that further structure-activity relationship (SAR) study is
necessary for identifying a highly specific PET radioligand targeting α-syn aggregation.
Figure 1. Potent tricyclic aromatic ring analogues. a Thioflavin T fluorescence assay; b 125I
competitive binding assay; c 95% confidence intervals for Ki values are shown
in parentheses.
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2. Experimental Section
2.1. Chemistry
2.1.1. General
All reagents and chemicals were purchased from Sigma-Aldrich Corporation (Milwaukee, WI,
USA) and used without further purification, unless otherwise stated. The melting points of all
intermediates and final compounds were determined on a Haake-Buchler melting point apparatus and
are uncorrected. 1H and 13C NMR spectra were recorded on a Varian-400 MHz spectrometer (Varian
Inc. Palo Alto, CA, USA), which is maintained by the Chemistry Department of Washington
University in St. Louis, MO, USA. Spectra are referenced to the deuterium lock frequency of the
spectrometer. The chemical shifts (in parts per million) of residual solvents were found to be at 7.26
for CHCl3 and at 2.50 for dimethyl sulfoxide (DMSO).

Appl. Sci. 2014, 4

69

Compound 4, the precursor for radiolabeling [11C]2a and [18F]2b, was synthesized according to
Scheme 1 and the previously reported procedure [17] with necessary modification.
Scheme 1. Synthesis of phenol Precursor 4. rt, room temperature. Reagents and conditions:
a AcCl, DCM, rt, overnight; b BBr3 in DCM (1.0 M), DCM, −78 °C–rt, overnight.

2.1.2. 1-(3-Methoxy-7-nitro-10H-phenothiazin-10-yl)ethanone (3)
Acetyl chloride (360 mg, 4.59 mmol) was added into the solution of Compound 2a (420 mg,
1.53 mmol) in dichloromethane (10 mL). The reaction mixture was stirred overnight at room
temperature (rt). The solvent and excess acetyl chloride was removed under reduced pressure. The
residue was dissolved in ethyl acetate and washed with water and saturated sodium chloride solution.
The organic extract was dried over anhydrous Na2SO4 and purified by silica gel column
chromatography using ethyl acetate/hexane (1/2, v/v) as the mobile phase to yield Compound 3 as a
yellow solid (267 mg, 55%). 1H NMR (CDCl3): δ 2.23 (s, 3H), 3.83 (s, 3H), 6.90 (d, J = 9.0 Hz, 1H),
6.98 (s, 1H), 7.32 (d, J = 8.7 Hz, 1H), 7.72 (d, J = 8.7 Hz, 1H), 8.18 (d, J = 8.7 Hz, 1H), 8.29 (s, 1H).
13
C NMR (CDCl3): δ 22.9, 55.7, 112.7, 114.0, 122.0, 122.9, 127.4, 127.9, 130.7, 133.2, 134.3, 144.7,
145.6, 158.5, 169.2. Combustion elemental analysis (anal.) calculated (calcd.) for C15H12N2O4S: C,
56.95; H, 3.82; N, 8.86. Found: C, 56.72; H, 3.89; N, 8.70. mp 155.9–156.8 °C.
2.1.3. 1-(3-Hydroxy-7-nitro-10H-phenothiazin-10-yl)ethanone (4)
A solution of BBr3 in dichloromethane (1.0 M, 4.2 mL) was added dropwise to a solution of
Compound 3 (267.3 mg, 0.84 mmol) in dichloromethane (15 mL) at −78 °C. The reaction solution was
stirred overnight at rt. The solvent was removed under reduced pressure. The residue was partitioned
between ethyl acetate and water. The organic extract was dried over anhydrous Na2SO4 and purified by
silica gel column chromatography using ethyl acetate/CH2Cl2 (1/10, v/v) as the mobile phase to yield
Compound 4 as a yellow solid (207.4 mg, 81%). 1H NMR (DMSO-d6): δ 2.15 (s, 3H), 6.82 (d,
J = 9.0 Hz, 1H), 6.93 (s, 1H), 7.47 (d, J = 9.0 Hz, 1H), 7.82 (d, J = 9.0 Hz, 1H), 8.22 (d, J = 9.0 Hz,
1H), 8.39 (s, 1H), 10.00 (br s, 1H). 13C NMR (DMSO-d6): δ 23.0, 114.3, 115.3, 122.6, 123.2, 128.4,
128.5, 129.3, 132.3, 134.2, 145.1, 145.6, 156.7, 169.1. High resolution mass spectrometry (HRMS,
ESI): m/z calcd. for C14H10N2O4S [M + 1] 303.0440. Found: 303.0435. Purity: 98% (HPLC
confirmed). mp 202.3–205.1 °C.
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2.2. Radiochemistry
2.2.1. Radiosynthesis of [11C]2a
2.2.1.1. Production of [11C]CH3I
Briefly, [11C]CH3I was produced from [11C]CO2 using a GE PETtrace MeI Microlab (GE
Healthcare, Fairfield, CT, USA). Up to 51.8 GBq of [11C]CO2 is produced from Washington
University’s Japan Steel Works BC-16/8 cyclotron by irradiating a gas target of 0.2% O2 in N2 for
15–30 min with a 40 µA beam of 16 MeV protons. The GE PETtrace MeI Microlab coverts the
[11C]CO2 to [11C]CH4 using a nickel catalyst (Shimalite-Ni, Shimadzu, Japan P.N.221-27719) in the
presence of hydrogen gas at 360 °C; it is further converted to [11C]CH3I by reacting with iodine held in
a column in the gas phase at 690 °C. Approximately 12 min after the end of bombardment (EOB),
several hundred millicuries of [11C]CH3I was delivered as a gas to the hot cell, where the
radiosynthesis was accomplished.
Scheme 2. Synthesis of [11C]2a and [18F]2b. DMF, N,N-dimethylformamide;
[18F]fluoroethyltosylate;
DMSO,
dimethyl
sulfoxide;
DBU,
[18F]FEOTs,
11
1,8-diazabicyclo[5.4.0]undec-7-ene. Reagents and conditions: a [ C]CH3I/DMF, NaOH,
90 °C, 5 min; b DBU, 7 min; c [18F]F−, Kryptofix 2.2.2, K2CO3, CH3CN, 110 °C, 10 min;
d [18F]FEOTs, Cs2CO3, DMSO, 90 °C, 15 min; e DBU, 15 min.

2.2.1.2. Radiosynthesis of [11C]2a
Approximately 1.2 mg of Precursor 4 was placed in the reaction vessel, and 0.20 mL of DMF was
added, followed by 3.0 µL of 5 N NaOH. The mixture was thoroughly mixed on a vortex for 30 s. A
stream of [11C]CH3I in helium was bubbled for 3 min into the reaction vessel. The sealed vessel was
heated at 90 °C for 5 min, at which point the vessel was removed from heat and
20 µL 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) in 50 µL DMF was added via syringe. The reaction
mixture was heated at 90 °C for 7 min (Scheme 2); then, the reaction was quenched by adding 1.7 mL
of the HPLC mobile phase, which was composed of acetonitrile/0.1 M ammonium formate buffer
(60/40, v/v) and pH = 4.5. The diluted solution was purified by high performance liquid

Appl. Sci. 2014, 4

71

chromatography (HPLC) by injection on a Phenomenex Luna C18 reverse phase column
(9.4 × 250 mm) using the mobile phase described above. The radiolabeled product was eluted using a
flow rate of 4.0 mL/min, and the UV wavelength was set as 254 nm. Under these conditions, the
retention time of Precursor 4 was ~7 min; the retention time of [11C]2a was ~16 min. [11C]2a was
collected in a vial containing 50 mL Milli-Q water, which was then passed through a Sep-Pak Plus
C18 cartridge (Waters, Milford, MA, USA). The trapped product was eluted with ethanol (0.6 mL)
followed by 5.4 mL 0.9% saline. After sterile filtration, the final product was ready for quality control
(QC) analysis and animal studies. QC was performed on a Phenomenex Prodigy C18 reverse phase
analytic HPLC column (250 mm × 4.6 mm, 5 µA) and UV detection at a 254 nm wavelength. The
mobile phase was acetonitrile/0.1 M ammonium formate buffer (80/20, v/v) using a 1.5 mL/min flow
rate. Under these conditions, the retention time of [11C]2a was 4.82 min. The radioactive dose was
authenticated by co-injection with the cold standard Compound 2a. Radiochemical purity was >99%;
the chemical purity was >95%; the labeling yield was 35%–45% (n = 4, decay corrected to EOB), and
the specific activity was >363 GBq/µmol (decay corrected to EOB, n = 4).
2.2.2. Radiosynthesis of [18F]2b
2.2.2.1. Production of [18F]fluoride
[18F]Fluoride is produced by a 18O(p, n)18F reaction through proton irradiation of enriched 18O water
(95%) using Washington University’s RDS-111 cyclotron (Siemens/CTI Molecular Imaging,
Knoxville, TN, USA). [18F]Fluoride is first passed through an ion-exchange resin and then eluted with
0.02 M potassium carbonate (K2CO3) solution.
2.2.2.2. 2-[18F]Fluoroethyltosylate
A sample of approximately 5.55 GBq [18F]/fluoride was added to a reaction vessel containing
Kryptofix 222 (6.5–7.0 mg). The syringe was washed with 2 × 0.4 mL of ethanol. The resulting
solution was evaporated under nitrogen flow with a bath temperature of 110 °C. Acetonitrile
(3 × 1.0 mL) was added to the mixture, and water was azeotropically removed by evaporation. After
all the water was removed, 5.0–5.5 mg of 1,2-ethylene ditosylate was dissolved in acetonitrile
(200 μL), and the solution was transferred into the reaction vessel containing [18F]fluoride/Kryptofix
222/K2CO3. The reaction vessel was capped and the reaction mixture briefly mixed and then subjected
to heating in an oil bath that was preheated to 110 °C for 10 min (Scheme 2).
After heating for 10 min, the reaction mixture was diluted with 3.0 mL of the HPLC mobile phase
(50/50 acetonitrile/0.1 M ammonium formate buffer, pH = 6.5) and passed through an alumina neutral
Sep-Pak Plus cartridge (Waters Corporation, Milford, MA, USA). The crude product was then loaded
onto an Agilent SB-C18 semi-preparative HPLC column (250 mm × 10 mm) with a UV detector set at
254 nm. The HPLC system used a 5 mL injection loop. At a 4.0 mL/min flow rate, the retention time
of the product was 9.5–10 min. The retention time of the precursor was 23–24 min. The radioactivity
peak observed on HPLC was collected and diluted with 50 mL sterile water and the diluted collection
went through a C-18 Sep-Pak Plus cartridge to trap the 2-[18F]fluoroethyl tosylate on the Sep-Pak. The
trapped product was eluted with diethyl ether (2.5 mL).
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2.2.2.3. Radiosynthesis of [18F]2b
The eluted solution formed two phases: the top ether phase was transferred out, and the bottom
aqueous phase was extracted with another 1-mL aliquot of ether. The combined ether extracts were
passed through a set of two sodium sulfate Sep-Pak Plus dry cartridges into a reaction vessel. After
ether was evaporated with a nitrogen stream at 25 °C, 1.0 mg of Precursor 4 was dissolved in 200 µL
DMSO and was transferred to a vial containing 1–2 mg Cs2CO3. After vortexing for 1 min, the Cs2CO3
saturated solution was added to the reaction vessel containing the dried radioactive [18F]/F−. The tube
was capped and briefly vortexed and then kept at 90 °C for 15 min. Ten microliters of
1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) in 50 µL DMSO was added via syringe. The reaction
mixture was heated at 90 °C for 15 min. The mixture was subsequently diluted with 3 mL of the HPLC
mobile phase (50/50 acetonitrile/0.1 M formate buffer, pH = 4.5) and purified using a Semi-Prep
HPLC system for purification. The HPLC system contains a 5-mL injection loop, an Agilent SB C-18
column, a UV detector at 254 nm and a radioactivity detector. At a 4.0 mL/min flow rate, the retention
time of the product was 19–21 min, whereas the retention time of the precursor was 8–9 min. After the
HPLC collection and being diluted with 50 mL sterile water, the product was trapped on a C18
Sep-Pak Plus cartridge. The product was eluted with ethanol (0.6 mL) followed by 5.4 mL 0.9% saline.
After sterile filtration, the final product was ready for quality control (QC) analysis and animal studies.
An aliquot was assayed by analytical HPLC (Grace Altima C18 column, 250 × 4.6 mm), UV at
276 nm, mobile phase of acetonitrile/0.1 M ammonium formate buffer (71/29, v/v), pH = 4.5. Under
these conditions, the retention time for [18F]2b was approximately 4.9 min at a flow rate of
1.5 mL/min. The sample was authenticated by co-injecting with the cold standard 2b solution. The
radiochemical purity was >98%; the chemical purity was >95%; the labeling yield was 55%–65%
(n = 4, decay corrected), and the specific activity was >200 GBq/µmol (decay corrected to EOB, n = 4).
2.3. Biodistribution Studies
All animal experiments were conducted in compliance with the Guidelines for the Care and Use of
Research Animals under protocols approved by Washington University’s Animal Studies Committee.
For the biodistribution studies, 11.1–13.0 MBq of [11C]2a in 200–250 µL or 1.67–1.85 MBq of [18F]2b
in 200–250 µL of saline containing 10% ethanol was injected via the tail vein into mature male
Sprague-Dawley rats (175–240 g) under 2%–3% isoflurane/oxygen anesthesia. Group of rats (n = 4)
were used for each time point. At 5, 30, 60 min (and 120 min for [18F]2b) post injection, the rats were
anesthetized and euthanized. The whole brain was quickly removed and dissected into segments
consisting of brain stem, thalamus, striatum, hippocampus, cortex and cerebellum. The remainder of
the brain was also collected to determine total brain uptake. At the same time, samples of blood, heart,
lung, muscle, fat, pancreas, spleen, kidney, liver (and bone for [18F]2b) were removed and counted in a
Beckman Gamma 8000 well counter with a standard dilution of the injectate. Tissues were weighed,
and the percent injected dose (%ID)/gram for each tissue was calculated.
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2.4. MicroPET Brain Imaging Studies of [11C]2a in Cynomolgus Macaque
Following the initial evaluation in rats, the washout kinetics and ability of [11C]2a to cross the
blood-brain barrier in a non-human primate (NHP) was determined on an adult male cynomolgus
macaque (6−8 kg) using a microPET Focus 220 scanner (Concorde/CTI/Siemens Microsystems,
Knoxville, TN). Before each scan (n = 2), the animal was fasted for 12 h and then initially anesthetized
with ketamine (10 mg/kg) and glycopyrrolate (0.13 mg/kg) intramuscularly. Upon arrival at the
scanner, the monkey was intubated, and a percutaneous catheter placed for tracer injection. The head
was positioned supine in the adjustable head holder with the brain in the center of the field of view.
Anesthesia was maintained at 0.75%−2.0% isoflurane/oxygen and the core temperature maintained at
37 °C. A 10-min transmission scan was performed to confirm positioning; this was followed by a
45-min transmission scan for attenuation correction. Subsequently, a 2-h dynamic emission scan was
acquired after venous injection of 300−370 MBq of [11C]2a.
3. Results and Discussions
3.1. Chemistry
Compounds 2a and 2b possess a methoxy and fluoroethoxy group, respectively, enabling
radiolabeling through O-alkylation of the corresponding phenol precursor. However, to avoid
undesired N-alkylation product, the acetyl protected Compound 4 was used as the precursor for the
radiosyntheses. As shown in Scheme 1, the synthesis of 4 was accomplished by a two-step strategy
starting from 2a following our previous procedure [17]. N-acetylation of 2a was achieved using acetyl
chloride. Removing the O-methyl group of 3 with boron tribromide afforded the phenol Precursor 4,
which was used in the radiosyntheses of 2a and 2b. Due to the reaction scale difference, the yields for
certain reactions differ slightly from our previous report.
3.2. Radiochemistry
The radiosynthesis of [11C]2a was accomplished by a two-step approach. The reaction of the phenol
Precursor 4 with [11C]CH3I was performed in DMF in the presence of NaOH [19–21], and the N-acetyl
group of the 11C-labeled intermediate was removed by DBU following the literature procedure [22], as
outlined in Scheme 2. [11C]2a was obtained in approximately 35%–45% overall radiochemical yield
(RCY) after HPLC purification (n = 4). The radiochemical purity of [11C]2a was >99% and chemical
purity was >95%. [11C]2a was identified by co-eluting with the solution of standard 2a. The entire
synthetic procedure, including the production of [11C]CH3I, radiosynthesis, HPLC purification and
formulation of the radiotracer for animal studies, was completed within 50–60 min. [11C]2a was
obtained in a specific activity of >363 GBq/µmol at EOB (n = 4).
The radiosynthesis of [18F]2b was achieved using a three-step reaction. The radioactive
intermediate, [18F]fluoroethyltosylate ([18F]FEOTs), was first synthesized through a typical
fluorination of the di-tosylate substrate [23–27]. Treatment of ethylene glycol ditosylate using
[18F]fluoride, potassium carbonate and Kryptofix 222 gave [18F]FEOTs in good yield (60%–70%,
decay corrected) after HPLC purification. The intermediate was reacted with the precursor, followed
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by DBU hydrolysis to afford a sufficient dose of [18F]2b with the labeling yield of 55%–65% after
HPLC purification (n = 4, decay corrected to EOB). The radiochemical purity of [18F]2b was >98%,
and the chemical purity was >95%. [18F]2b was identified by co-eluting with the solution of standard
2b. The entire synthetic procedure, including the drying of [18F]F−, the radiosynthesis, HPLC
purification and formulation of the radiotracer for in vivo studies, was completed in 3 h. Radiotracer
[18F]2b was obtained in a specific activity of >200 GBq/µmol (decay corrected to EOB, n = 4).
Table 1. Biodistribution of [11C]2a and [18F]2b in male Sprague-Dawley rats (%ID/gram).
Radioligand

[11C]2a

[18F]2b

Organ
blood
heart
lung
muscle
fat
pancreas
spleen
kidney
liver
brain
blood
heart
lung
muscle
fat
pancreas
spleen
kidney
liver
bone
brain

5 min
0.506 ± 0.040
0.758 ± 0.052
1.149 ± 0.058
0.271 ± 0.005
0.155 ± 0.023
1.007 ± 0.262
0.659 ± 0.049
1.362 ± 0.054
2.198 ± 0.111
0.953 ± 0.115
0.553 ± 0.047
0.757 ± 0.033
0.833 ± 0.053
0.430 ± 0.031
0.255 ± 0.037
1.004 ± 0.147
0.672 ± 0.064
1.070 ± 0.058
1.626 ± 0.221
0.340 ± 0.027
0.758 ± 0.013

30 min
0.369 ± 0.031
0.377 ± 0.046
0.740 ± 0.038
0.325 ± 0.030
0.241 ± 0.042
0.506 ± 0.066
0.400 ± 0.052
0.807 ± 0.086
1.349 ± 0.116
0.287 ± 0.046
0.589 ± 0.016
0.505 ± 0.015
0.561 ± 0.021
0.451 ± 0.018
0.425 ± 0.023
0.546 ± 0.068
0.509 ± 0.022
0.988 ± 0.090
0.847 ± 0.027
0.309 ± 0.020
0.465 ± 0.018

60 min
0.300 ± 0.015
0.245 ± 0.010
0.485 ± 0.036
0.199 ± 0.016
0.293 ± 0.076
0.522 ± 0.036
0.386 ± 0.027
0.559 ± 0.053
1.116 ± 0.024
0.158 ± 0.013
0.606 ± 0.035
0.466 ± 0.040
0.491 ± 0.030
0.376 ± 0.019
0.371 ± 0.067
0.409 ± 0.029
0.446 ± 0.038
0.678 ± 0.032
0.561 ± 0.028
0.407 ± 0.043
0.410 ± 0.030

120 min

0.585 ± 0.046
0.410 ± 0.030
0.436 ± 0.018
0.315 ± 0.015
0.293 ± 0.048
0.330 ± 0.021
0.398 ± 0.019
0.659 ± 0.027
0.467 ± 0.023
0.644 ± 0.071
0.359 ± 0.016

3.3. Biodistribution in Rats
The radioactivity distribution in various organs after the injection of [11C]2a and [18F]2b in rats is
summarized in Table 1. Both radiotracers displayed homogeneous distribution in the brain regions as
shown in Figure 2A,B. For [11C]2a, the total brain uptake (%ID/gram) of radioactivity at five, 30 and
60 min post injection were 0.953 ± 0.115, 0.287 ± 0.046 and 0.158 ± 0.014 respectively; in the
peripheral tissues, liver had the highest uptake among the tissues analyzed; the uptake (%ID/gram) in
liver reached 2.198 ± 0.111 at 5 min and 1.116 ± 0.024 at 60 min. For [18F]2b, the total brain uptake
(%ID/gram) at five, 30, 60 and 120 min was 0.758 ± 0.013, 0.465 ± 0.018, 0.410 ± 0.030 and
0.359 ± 0.016, respectively; At 5 min post-injection, this compound also has a high liver uptake:
(%ID/gram) of 1.626 ± 0.221. However, after 30 min, the kidney has retained the highest radioactivity
of all tissues that were analyzed. The bone uptake (%ID/gram) was very stable and no defluorination
was observed for [18F]2b. More importantly, the ex vivo rat biodistribution data revealed that both
compounds readily crossed the BBB and entered the brain. Both tracers exhibit high initial brain
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uptake and appropriate washout kinetics in the brain of normal rats. Rapid clearance of the
radioactivity for both [11C]2a and [18F]2b was observed from brain, as well as other organs, such as
lung, pancreas, spleen, kidney and liver. However, [11C]2a showed faster wash-out kinetics than
[18F]2b, as shown in Figure 2. [11C]2a was chosen for subsequent microPET evaluation in an NHP.
Figure 2. Regional radioactivity uptake in male Sprague Dawley (SD) rat brain (n = 4).
(A) Regional brain uptake of [11C]2a; (B) regional brain uptake of [18F]2b. Cb, cerebellum;
Ctx, cortex; Str, striatum; Thal, thalamus; Hippo, hippocampus.

3.4. MicroPET Studies in NHP
The representative summed images from zero to 120 min were co-registered with MRI images to
accurately identify the regions of interest (Figure 3). The time-activity curve (TAC) revealed high
initial uptake of [11C]2a in the brain, which peaked at 3 min post-injection; then, the radioactivity was
quickly washed out from all brain regions. The summed image revealed a homogeneous distribution of
radioactivity in the brain of the normal cynomolgus macaque. The microPET studies suggested that
[11C]2a was able to cross the BBB and had a fast washout kinetics from the brain regions. The
macaque used in the studies was a healthy young adult, and the distribution of the α-syn radioligand
throughout the brain regions was homogeneous. Higher expression of α-syn protein in particular
regions should not be observed in healthy subjects; thus, homogeneous distribution of the radioactivity
in the macaque brain was expected. Nevertheless, PET studies of [11C]2a performed on an NHP model
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bearing the over-expression of α-syn aggregation will directly determine the in vivo specificity of
the radiotracer.
Figure 3. In vivo microPET brain imaging studies of [11C]2a in cynomolgus macaque. (A)
PET image (left), co-registered with MRI (middle), MRI image (right);
(B) time-activity curves. SUV, standardized uptake value.

4. Conclusions
In summary, two α-syn ligands, [11C]2a and [18F]2b, were successfully radiosynthesized by
O-alkylation of the desalkyl precursor. The biodistribution studies of [11C]2a and [18F]2b were
conducted in male Sprague-Dawley rats and showed that both tracers were able to cross the BBB with
high initial uptake. At 5 min post-injection, the uptake (%ID/gram) reached 0.953 ± 0.115 for [11C]2a
and 0.758 ± 0.013 for [18F]2b. Both [11C]2a and [18F]2b displayed a homogeneous distribution
throughout the brain of healthy adult male rats with rapid washout kinetics. In vivo microPET imaging
in a healthy cynomolgus macaque confirmed that [11C]2a was able to enter the brain, had
homogeneous distribution and rapid washout kinetics. Further structural optimization of [11C]2a and
[18F]2b may lead to a highly specific radioligand for imaging α-syn aggregation in vivo.
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